Recursion Pharmaceuticals (RXRX) EBT Margin Growth (3y) (2023 - 2026)

Recursion Pharmaceuticals (RXRX) EBT Margin Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 9,237.00
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 441.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -408.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 363.00
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Recursion Pharmaceuticals 1.59 Bn 933.22 Mn -6.02 Mn -134,833.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -134,833.00
Dec 31, 2025 16,773.00
Sep 30, 2025 -265,969.00
Jun 30, 2025 -3,151.00
Mar 31, 2025 -32,436.00
Dec 31, 2024 -137,017.00
Sep 30, 2024 147,303.00
Jun 30, 2024 102,362.00
Mar 31, 2024 53,171.00
Dec 31, 2023 6,561.00
Sep 30, 2023 134,861.00
Jun 30, 2023 932,669.00
Mar 31, 2023 3.05 Mn